Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-03-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物2023年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2023年度董事会审计委员会履职情况报告" which translates to "2023 Annual Board Audit Committee Performance Report." It details the audit committee's activities, meetings, oversight of external and internal audits, review of financial reports, and internal control evaluations for the year 2023. The content focuses on audit committee duties and audit-related evaluations rather than presenting full financial statements or comprehensive annual financial performance. It is a report on audit committee work rather than a standalone audit report or full annual report. Given the focus on audit committee activities and oversight, this fits best under the category of Audit Report / Information (AR). The document length is 2444 characters, which is relatively short but contains substantive audit committee information, not just an announcement or certification. Therefore, the classification is AR with high confidence. FY 2023
2024-03-29 Chinese
前沿生物药业（南京）股份有限公司信息披露管理办法
Governance Information Classification · 95% confidence The document is a detailed internal policy manual titled "Information Disclosure Management Measures" for a company, outlining the principles, responsibilities, and procedures for information disclosure. It references various regulatory laws and rules such as the Securities Law, Shanghai Stock Exchange rules, and China Securities Regulatory Commission requirements. The content covers definitions, disclosure obligations, types of reports (annual, interim, quarterly), temporary announcements, and the roles of company officers in disclosure management. It does not contain actual financial data, financial statements, audit opinions, or earnings results. Instead, it is a governance and compliance document detailing how the company manages and controls its information disclosure processes. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices related to disclosure.
2024-03-29 Chinese
前沿生物药业（南京）股份有限公司监事会议事规则
Governance Information Classification · 95% confidence The document is titled as the "Supervisory Board Meeting Rules" of a company, detailing the governance structure, composition, powers, meeting procedures, and record-keeping of the supervisory board. It references relevant laws and company articles but does not contain financial data, audit results, or announcements of financial performance. It is a governance-related internal rules document rather than a report, announcement, or financial filing. Therefore, it fits best under Governance Information (CGR). The document length is 4470 characters, which is sufficient for a detailed governance document, not a brief announcement.
2024-03-29 Chinese
前沿生物2023年度独立董事述职报告-KAI CHEN（陈凯）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's background, attendance at board meetings, committee work, communication with auditors, and overall evaluation of the company's governance and financial reporting during the year 2023. The content focuses on the independent director's duties, observations, and opinions rather than presenting financial statements or audit results. It is a report on the independent director's management and governance activities rather than a full annual report, audit report, or other financial filings. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities and evaluations. The document length is 3732 characters, which is relatively short but contains substantive content about the independent director's role and activities, not just an announcement or notice. Therefore, the classification is MANG with high confidence.
2024-03-29 Chinese
前沿生物关于修改《公司章程》及公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from a company about amendments to its Articles of Association (公司章程) and revisions to several corporate governance systems. It includes specific changes to governance rules, board committee responsibilities, shareholder meeting procedures, and profit distribution policies. The document is not a financial report, earnings release, or audit report, but rather a governance-related disclosure. It is also not a brief announcement or a notice of voting results but a substantive governance update. The content aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is lengthy and detailed, indicating it is the actual governance information rather than a mere announcement of such a report.
2024-03-29 Chinese
前沿生物药业（南京）股份有限公司独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and contains detailed rules, qualifications, duties, and procedures related to independent directors of the company. It references relevant laws, regulations, and stock exchange rules, focusing on governance and board structure. There is no financial data, earnings information, or report publication announcement. The content is a governance document detailing internal rules and practices for independent directors, fitting the Governance Information category.
2024-03-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.